✦ LIBER ✦

Bevacizumab + capecitabine not cost effective in mCRC

✍ Scribed by Ritter, M.; Mußhoff, O.; Odening, M.

Book ID: 121596690
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2013
Weight: 111 KB
Volume: 692
Category: Article
ISSN: 1173-5503
DOI: 10.1007/s40274-013-0906-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bevacizumab not cost effective in ovaria

Bevacizumab not cost effective in ovarian cancer

✍ Lancsar, Emily; Swait, Joffre 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl ⚖ 111 KB

Bevacizumab not cost effective in advanc

Bevacizumab not cost effective in advanced ovarian cancer

✍ Naik, Haladhara; Goswami, Ashok; Kim, Guinyun; Kim, Kwangsoo; Yang, Sung-Chul; S 📂 Article 📅 2014 🏛 Adis International Limited (now part of Wolters Kl ⚖ 199 KB

Are monoclonal antibodies cost effective

Are monoclonal antibodies cost effective in mCRC?

📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl ⚖ 111 KB

Capecitabine cost effective in colorecta

Capecitabine cost effective in colorectal cancer management

📂 Article 📅 2006 🏛 Adis International Limited (now part of Wolters Kl ⚖ 140 KB

Tolvaptan effective, but not cost effect

Tolvaptan effective, but not cost effective, in ADPKD

📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl ⚖ 128 KB

In vitro fertilisation not cost effectiv

In vitro fertilisation not cost effective

✍ Greener, Mark 📂 Article 📅 1999 🏛 Adis International Limited (now part of Wolters Kl ⚖ 221 KB